- Home
- SSSS vs ACHV Comparison
SSSS vs ACHV Comparison
Compare SSSS & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- ACHV
- Stock Information
- Founded
- SSSS 2010
- ACHV N/A
- Country
- SSSS United States
- ACHV United States
- Employees
- SSSS N/A
- ACHV N/A
- Industry
- SSSS Finance: Consumer Services
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SSSS Finance
- ACHV Health Care
- Exchange
- SSSS Nasdaq
- ACHV Nasdaq
- Market Cap
- SSSS 138.2M
- ACHV 153.8M
- IPO Year
- SSSS N/A
- ACHV N/A
- Fundamental
- Price
- SSSS $9.98
- ACHV $3.22
- Analyst Decision
- SSSS Strong Buy
- ACHV Strong Buy
- Analyst Count
- SSSS 4
- ACHV 2
- Target Price
- SSSS $9.50
- ACHV $16.00
- AVG Volume (30 Days)
- SSSS 186.1K
- ACHV 867.2K
- Earning Date
- SSSS 11-06-2025
- ACHV 11-06-2025
- Dividend Yield
- SSSS 10.67%
- ACHV N/A
- EPS Growth
- SSSS N/A
- ACHV N/A
- EPS
- SSSS 2.22
- ACHV N/A
- Revenue
- SSSS $2,784,381.00
- ACHV N/A
- Revenue This Year
- SSSS $7,183.09
- ACHV N/A
- Revenue Next Year
- SSSS N/A
- ACHV N/A
- P/E Ratio
- SSSS $4.22
- ACHV N/A
- Revenue Growth
- SSSS N/A
- ACHV N/A
- 52 Week Low
- SSSS $3.87
- ACHV $1.84
- 52 Week High
- SSSS $9.50
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- SSSS 74.65
- ACHV 58.10
- Support Level
- SSSS $8.75
- ACHV $3.07
- Resistance Level
- SSSS $9.40
- ACHV $3.26
- Average True Range (ATR)
- SSSS 0.25
- ACHV 0.14
- MACD
- SSSS 0.05
- ACHV 0.01
- Stochastic Oscillator
- SSSS 99.05
- ACHV 84.69
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.